269 related articles for article (PubMed ID: 17681669)
1. Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells.
Gleixner KV; Rebuzzi L; Mayerhofer M; Gruze A; Hadzijusufovic E; Sonneck K; Vales A; Kneidinger M; Samorapoompichit P; Thaiwong T; Pickl WF; Yuzbasiyan-Gurkan V; Sillaber C; Willmann M; Valent P
Exp Hematol; 2007 Oct; 35(10):1510-21. PubMed ID: 17681669
[TBL] [Abstract][Full Text] [Related]
2. KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406).
Peter B; Hadzijusufovic E; Blatt K; Gleixner KV; Pickl WF; Thaiwong T; Yuzbasiyan-Gurkan V; Willmann M; Valent P
Exp Hematol; 2010 Sep; 38(9):782-91. PubMed ID: 20685234
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.
Böhm A; Sonneck K; Gleixner KV; Schuch K; Pickl WF; Blatt K; Peter B; Herrmann H; Schernthaner GH; Pehamberger H; Rabitsch W; Sperr WR; Valent P
Exp Hematol; 2010 Sep; 38(9):744-55. PubMed ID: 20553795
[TBL] [Abstract][Full Text] [Related]
4. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
Gleixner KV; Mayerhofer M; Sonneck K; Gruze A; Samorapoompichit P; Baumgartner C; Lee FY; Aichberger KJ; Manley PW; Fabbro D; Pickl WF; Sillaber C; Valent P
Haematologica; 2007 Nov; 92(11):1451-9. PubMed ID: 18024392
[TBL] [Abstract][Full Text] [Related]
5. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.
Pryer NK; Lee LB; Zadovaskaya R; Yu X; Sukbuntherng J; Cherrington JM; London CA
Clin Cancer Res; 2003 Nov; 9(15):5729-34. PubMed ID: 14654558
[TBL] [Abstract][Full Text] [Related]
6. Identification of c-kit mutations-independent neoplastic cell proliferation of canine mast cells.
Ohmori K; Kawarai S; Yasuda N; Tanaka A; Matsuda H; Nishimura R; Sasaki N; Tsujimoto H; Masuda K
Vet Immunol Immunopathol; 2008 Nov; 126(1-2):43-53. PubMed ID: 18687474
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis.
Juurikivi A; Sandler C; Lindstedt KA; Kovanen PT; Juutilainen T; Leskinen MJ; Mäki T; Eklund KK
Ann Rheum Dis; 2005 Aug; 64(8):1126-31. PubMed ID: 16014680
[TBL] [Abstract][Full Text] [Related]
8. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant.
Shivakrupa R; Bernstein A; Watring N; Linnekin D
Cancer Res; 2003 Aug; 63(15):4412-9. PubMed ID: 12907613
[TBL] [Abstract][Full Text] [Related]
9. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
Puttini M; Redaelli S; Moretti L; Brussolo S; Gunby RH; Mologni L; Marchesi E; Cleris L; Donella-Deana A; Drueckes P; Sala E; Lucchini V; Kubbutat M; Formelli F; Zambon A; Scapozza L; Gambacorti-Passerini C
Haematologica; 2008 May; 93(5):653-61. PubMed ID: 18367480
[TBL] [Abstract][Full Text] [Related]
10. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
Sotlar K
Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
[TBL] [Abstract][Full Text] [Related]
11. Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.
Ren H; Tan X; Dong Y; Giese A; Chou TC; Rainov N; Yang B
Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):241-52. PubMed ID: 19159435
[TBL] [Abstract][Full Text] [Related]
12. Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.
Peter B; Bibi S; Eisenwort G; Wingelhofer B; Berger D; Stefanzl G; Blatt K; Herrmann H; Hadzijusufovic E; Hoermann G; Hoffmann T; Schwaab J; Jawhar M; Willmann M; Sperr WR; Zuber J; Sotlar K; Horny HP; Moriggl R; Reiter A; Arock M; Valent P
Leukemia; 2018 Apr; 32(4):1016-1022. PubMed ID: 29249817
[TBL] [Abstract][Full Text] [Related]
13. The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells.
Peter B; Cerny-Reiterer S; Hadzijusufovic E; Schuch K; Stefanzl G; Eisenwort G; Gleixner KV; Hoermann G; Mayerhofer M; Kundi M; Baumgartner S; Sperr WR; Pickl WF; Willmann M; Valent P
J Leukoc Biol; 2014 Jan; 95(1):95-104. PubMed ID: 24052572
[TBL] [Abstract][Full Text] [Related]
14. Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis.
Hadzijusufovic E; Rebuzzi L; Gleixner KV; Ferenc V; Peter B; Kondo R; Gruze A; Kneidinger M; Krauth MT; Mayerhofer M; Samorapoompichit P; Greish K; Iyer AK; Pickl WF; Maeda H; Willmann M; Valent P
Exp Hematol; 2008 Nov; 36(11):1461-70. PubMed ID: 18723263
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility of the C2 canine mastocytoma cell line to the effects of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Elders RC; Baines SJ; Catchpole B
Vet Immunol Immunopathol; 2009 Jul; 130(1-2):11-6. PubMed ID: 19185923
[TBL] [Abstract][Full Text] [Related]
16. The tyrosine kinase inhibitor imatinib [STI571] induces regression of xenografted canine mast cell tumors in SCID mice.
Kobie K; Kawabata M; Hioki K; Tanaka A; Matsuda H; Mori T; Maruo K
Res Vet Sci; 2007 Apr; 82(2):239-41. PubMed ID: 16919303
[TBL] [Abstract][Full Text] [Related]
17. Baseline and stimulated turnover of cell surface c-Kit expression in different types of human mast cells.
Babina M; Rex C; Guhl S; Thienemann F; Artuc M; Henz BM; Zuberbier T
Exp Dermatol; 2006 Jul; 15(7):530-7. PubMed ID: 16761962
[TBL] [Abstract][Full Text] [Related]
18. Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.
Hadzijusufovic E; Peter B; Rebuzzi L; Baumgartner C; Gleixner KV; Gruze A; Thaiwong T; Pickl WF; Yuzbasiyan-Gurkan V; Willmann M; Valent P
Vet Immunol Immunopathol; 2009 Dec; 132(2-4):243-50. PubMed ID: 19505729
[TBL] [Abstract][Full Text] [Related]
19. KIT mutations in mastocytosis and their potential as therapeutic targets.
Gotlib J
Immunol Allergy Clin North Am; 2006 Aug; 26(3):575-92. PubMed ID: 16931294
[TBL] [Abstract][Full Text] [Related]
20. Biological effect of tyrosine kinase inhibitors on three canine mast cell tumor cell lines with various KIT statuses.
Takeuchi Y; Fujino Y; Fukushima K; Watanabe M; Nakagawa T; Ohno K; Sasaki N; Sugano S; Tsujimoto H
J Vet Pharmacol Ther; 2012 Feb; 35(1):97-104. PubMed ID: 21480930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
